Brookline initiated coverage of Aileron Therapeutics with a Buy rating and $7 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALRN:
- Aileron Therapeutics Announces New Interim CFO Appointment
- Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Aileron Therapeutics to Present at Two Upcoming Investor Conferences
- Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
- Aileron Therapeutics 4.27M share Direct Listing priced at $4.68
Questions or Comments about the article? Write to editor@tipranks.com